Physician Prescribing Investigation Lawyer for Controlled-Substance Allegations
A medical board prescribing investigation may focus on far more than how many prescriptions a physician wrote. The board may examine diagnoses, treatment rationale, dosage, duration, patient monitoring, prescription history, documentation, pharmacy information, risk assessment, and whether the physician complied with the professional and regulatory requirements that apply in the jurisdiction.
Ratliff Jackson LLP represents physicians and licensed professionals in professional licensing matters in Alabama, California, Hawaii, Michigan, New Jersey, Pennsylvania, and Washington, D.C.
Prescribing Investigations Are About More Than the Prescription
A board may begin with prescription data, a patient complaint, pharmacy information, another regulatory investigation, or a report from a health care institution. The defense should determine what the board believes the data shows and whether the patient-specific records support a different or more complete explanation.
Patient-Specific Clinical Judgment
The significance of a prescription may depend on the diagnosis, history, treatment alternatives, prior therapies, clinical response, risk factors, follow-up, and the physician's documented reasoning.
Prescribing Pattern Data
Prescription-monitoring information, pharmacy records, dosage patterns, combinations of medications, refill frequency, patient volume, or comparisons with other prescribers may prompt scrutiny, but those data should be evaluated in context.
Documentation
A board may examine whether the record supports the diagnosis, treatment plan, informed discussion, monitoring, continued prescribing, referrals, testing, or other decisions associated with controlled-substance treatment.
Regulatory Overlap
Prescribing cases may involve state medical-board authority, state controlled-substance rules, prescription-monitoring requirements, pharmacy information, criminal issues, or separate federal DEA concerns.
What to Do After Receiving a Prescribing Investigation Notice
Identify the Patients and Prescriptions at Issue
Determine whether the inquiry concerns a particular patient, a group of patients, one medication, several controlled substances, a period of prescribing activity, or a broader pattern identified through prescription data.
Preserve the Existing Record
Preserve patient charts, prescribing records, communications, treatment agreements, testing information, referral records, consultation material, pharmacy communications, and other information relevant to the prescribing decisions.
Do Not Rewrite the Clinical Record
The investigation should be answered from the existing evidence. A physician should not alter an existing medical record to improve the appearance of prior documentation after board scrutiny begins.
Identify the Governing Requirements
State prescribing rules, prescription-monitoring requirements, professional standards, controlled-substance regulations, and other obligations differ by jurisdiction. The applicable requirements should be verified before concluding that a prescribing practice complied with or violated a legal standard.
Evaluate Parallel Exposure
Determine whether the investigation overlaps with DEA registration, law enforcement, a pharmacy matter, employment, peer review, malpractice litigation, credentialing, or another licensing authority.
Records That May Matter in a Physician Prescribing Investigation
Controlled-substance investigations often require a patient-by-patient review. The relevant record may include much more than a prescription log.
Clinical Notes
History, examination findings, diagnoses, pain or symptom assessments, treatment response, medication decisions, follow-up, and changes in the treatment plan may help explain why prescribing continued or changed.
Prescription History
Medication, dosage, quantity, frequency, refill history, multiple controlled substances, and prescribing duration may be examined across individual patients and across the practice.
Prescription Monitoring Data
State prescription-monitoring records may show controlled-substance prescriptions from multiple prescribers or pharmacies and may become part of the board's evidence.
Testing and Monitoring
Toxicology testing, medication counts, follow-up assessments, specialist referrals, monitoring documentation, and other risk-management measures may become relevant where required or clinically indicated.
Patient Communications
Portal messages, telephone records, refill requests, missed appointments, warnings, medication discussions, and other communications may provide important context.
Outside Records
Prior treatment, emergency department records, pharmacy information, specialist evaluations, imaging, surgery records, mental-health treatment, or substance-use treatment information may affect the clinical chronology.
Allegations Medical Boards May Examine in Prescribing Cases
Prescribing Without Adequate Clinical Support
The board may question whether the diagnosis, examination, treatment history, documented symptoms, or clinical assessment supported the medication prescribed.
Inadequate Monitoring
Investigators may examine whether the physician appropriately followed the patient's response, risks, medication use, adverse effects, or evidence suggesting misuse or diversion.
High Dosage or Long-Term Prescribing
Dosage and duration may attract scrutiny, particularly when the board believes the record does not adequately explain continued prescribing or risk-benefit decisions.
Concurrent Controlled Substances
A board may closely examine combinations of medications, particularly where the combination may increase patient risk or require additional clinical justification and monitoring.
Prescription Monitoring Concerns
Depending on state law, the case may involve whether prescription-monitoring information was reviewed, what it showed, and how the physician responded to information about prescriptions from other sources.
Diversion or Nonmedical Use
Cases may involve allegations that the physician ignored warning signs, knowingly prescribed for nonmedical use, participated in diversion, or failed to respond appropriately to evidence that medication was not being used as intended.
Prescription Monitoring Data Can Be Evidence, Not the Entire Case
Prescription data can identify prescribing volume, medication combinations, dispensing locations, and other patterns. It does not necessarily explain the patient's condition, the physician's clinical reasoning, prior treatment failures, consultation history, or why treatment continued.
A meaningful defense may require connecting prescribing data to the underlying medical record. The question is not simply whether a prescription appears unusual when viewed in isolation. The relevant inquiry may include whether the physician's conduct complied with the particular legal and professional standards applicable to the patient and jurisdiction.
The CDC Opioid Guideline Is Guidance, Not a Universal Legal Standard
CDC's 2022 Clinical Practice Guideline provides recommendations for clinicians prescribing opioids for certain adult outpatients with acute, subacute, or chronic pain. CDC expressly states that the guideline is not a law or regulation, does not replace individualized clinical judgment, and should not be applied as an inflexible standard of care.
Patient-Centered Decisions
CDC describes the guideline as a tool for clinicians and patients to evaluate the benefits and risks of pain treatment in light of individual circumstances.
Not an Automatic Liability Rule
A board investigation should be analyzed under the actual state law, regulations, board standards, and evidence applicable to the physician rather than assuming that departure from a general guideline automatically proves misconduct.
Scope Matters
CDC identifies specific patient populations and settings to which its opioid recommendations apply and expressly excludes several categories of care.
State Requirements Remain Separate
State prescribing requirements, PDMP obligations, controlled-substance rules, documentation standards, and medical-board expectations must be researched independently.
When a Prescribing Case Creates DEA Exposure
A state medical-board investigation and a DEA matter are separate regulatory proceedings, but they can overlap. DEA states that an individual practitioner registration is based on state authority to practice medicine and handle controlled substances. State licensing authorities determine the practitioner's state authority to prescribe, dispense, or administer controlled substances.
A prescribing case may therefore require separate analysis of the physician's state medical license, state controlled-substance authority where applicable, and federal DEA registration.
Federal issues should not be assumed merely because the medical board is reviewing controlled substances. The actual scope of any DEA inquiry, administrative action, criminal investigation, or federal registration issue must be determined from the facts and applicable federal authority.
How Counsel Can Defend a Physician Prescribing Investigation
Analyze the Board's Theory
Determine whether the investigation is based on a patient complaint, data analysis, pharmacy information, another regulator, criminal allegations, a peer review matter, or another source.
Build the Patient Chronology
Organize diagnoses, prior therapies, medication changes, monitoring, consultations, patient communications, adverse events, testing, and follow-up to evaluate the full clinical record.
Identify the Actual Governing Rules
Counsel can review the applicable board regulations, controlled-substance statutes, prescribing requirements, PDMP rules, and agency procedures rather than relying on generalized assumptions.
Evaluate Expert Issues
When the investigation turns on medical judgment, expert review may help evaluate whether the treatment and prescribing were clinically supportable under the circumstances.
Prepare the Response
A response can address the actual allegations, explain the relevant clinical record, identify supporting evidence, and avoid unnecessary admissions or broad statements unsupported by the patient files.
Manage Parallel Proceedings
Where the same prescribing activity is being examined by DEA, law enforcement, an employer, a hospital, a pharmacy regulator, or another board, the defense should account for how statements or evidence in one matter may affect another.
How a Prescribing Investigation Can Become Formal Discipline
A medical board may close an investigation, continue gathering evidence, seek an agreed resolution, or initiate formal disciplinary proceedings depending on the evidence and the authority provided by the jurisdiction.
Once formal charges are filed, the case may involve expert testimony, patient records, prescribing data, witness testimony, motions, settlement negotiations, and an administrative hearing. The procedural rules must be verified for the particular licensing authority.
Learn more about medical license disciplinary hearing defense.
NPDB and Other Consequences of Prescribing Discipline
If a prescribing investigation results in qualifying formal discipline, the consequences may extend beyond the board order. Federal NPDB rules require state licensing authorities to report specified adverse licensing actions resulting from formal proceedings, including suspension, revocation, reprimand, censure, probation, and other qualifying actions.
DEA Registration
Discipline that affects state authority to handle controlled substances may create separate federal registration issues.
Hospital Credentialing
Prescribing discipline may become relevant to privilege applications, reappointment, peer review, medical staff matters, or institutional credentialing.
Employment and Payer Issues
Employment agreements, malpractice carriers, credentialing forms, payer participation, and other professional arrangements may impose separate disclosure or eligibility requirements.
Other Medical Licenses
Physicians licensed in several jurisdictions may face reporting obligations or reciprocal disciplinary proceedings after another board takes action.
Prescribing Discipline Can Create Problems in More Than One State
Controlled-substance prescribing rules are jurisdiction-specific. A physician who practices in several states should not assume that compliance with one state's requirements establishes compliance everywhere else.
If discipline is imposed in one jurisdiction, another licensing authority may require disclosure or may independently review the underlying conduct. The reporting obligation, disciplinary authority, and procedure must be evaluated separately in each jurisdiction.
Learn more about multi-state license defense and national board actions.
Prescribing Investigation Defense in Seven Jurisdictions
Ratliff Jackson LLP provides professional license defense in Alabama, California, Hawaii, Michigan, New Jersey, Pennsylvania, and Washington, D.C. Each jurisdiction has its own medical licensing structure and prescribing requirements.
Prescribing Allegations Can Move Through Several Licensing Stages
If the board has only recently contacted you, review our medical board investigation lawyer page for guidance concerning the investigative stage.
If formal charges have already been filed, visit our medical license disciplinary hearing lawyer page.
For broader physician licensing issues, visit our Medical License Defense page.
Controlled-Substance Prescribing Resources
Federal clinical guidance for certain outpatient opioid-prescribing decisions. CDC states that the guideline is not a law or inflexible standard of care.
Review the CDC guidelineFederal information concerning practitioner registration and controlled-substance authority.
Review DEA registration guidanceFSMB publishes policy resources concerning medical regulation and prescribing issues for state medical boards.
Review FSMB policy resourcesFederal guidance concerning reportable adverse state licensure actions.
Review NPDB licensing guidanceFrequently Asked Questions About Physician Prescribing Investigations
What can trigger a medical board prescribing investigation?
A prescribing investigation may arise from a patient complaint, prescription-monitoring information, pharmacy records, another health care professional, institutional review, law enforcement, another regulator, or other information received by the medical licensing authority.
Does a high prescribing volume prove improper prescribing?
No. Prescribing data may prompt scrutiny, but whether prescribing was professionally appropriate generally requires examination of the relevant patients, medical records, governing requirements, and clinical circumstances.
Can the medical board review prescription monitoring data?
Prescription-monitoring programs and board access rules are governed by state law. In prescribing investigations, PDMP information may become relevant evidence where the licensing authority is authorized to obtain or use it.
Does the CDC opioid guideline establish the legal standard of care?
Not by itself. CDC expressly states that its 2022 opioid guideline is clinical guidance, not a law or regulation, and that it should not be applied as an inflexible standard of care. The applicable legal and professional standards must be determined from the jurisdiction and facts involved.
Can a medical board prescribing case affect my DEA registration?
Potentially. DEA registration depends on the practitioner's state authority to handle controlled substances. If state authority is restricted, suspended, revoked, or otherwise affected, separate federal registration issues may arise.
Should I change or add to old patient notes after receiving a board notice?
A physician should not alter an existing medical record to improve the appearance of prior documentation. The existing record should be preserved and evaluated as part of the defense.
Can prescribing discipline be reported to the NPDB?
Yes, if the licensing action meets federal reporting criteria. State licensing authorities must report specified adverse licensure actions resulting from formal proceedings, including certain suspensions, revocations, reprimands, censures, probation, and other qualifying actions.
Can one prescribing case affect medical licenses in other states?
Potentially. Other licensing authorities may require disclosure or may independently review discipline imposed in another jurisdiction. Reporting and reciprocal discipline rules differ by jurisdiction.
Before You Explain the Prescribing Pattern, Review the Patient Record
If a medical board is investigating your prescribing, controlled-substance practices, documentation, prescription-monitoring activity, or related professional conduct, Ratliff Jackson LLP can evaluate the notice, patient records, regulatory framework, potential DEA issues, and professional consequences.
Discuss a Prescribing InvestigationCall (856) 209-3111 or email intake@ratliffjackson.com.